Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. - Wikidata - wikimedia - TriplyDB

Compliance with guidelines for patients with bladder cancer: variation in the delivery of care.

Compliance with guidelines for patients with bladder cancer: variation in the delivery of care.

http://www.wikidata.org/entity/Q35501135

about

Intravesical immunotherapy in nonmuscle invasive bladder cancer Bladder cancer biomarker discovery using global metabolomic profiling of urine Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).Better organized care via care pathways: A multicenter study Complications associated with single-dose, perioperative mitomycin-C for patients undergoing bladder tumor resection.Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions.Treatment and survival in patients with recurrent high-risk non-muscle-invasive bladder cancer Evaluation of national trends in the utilization of partial nephrectomy in relation to the publication of the American Urologic Association guidelines for the management of clinical T1 renal masses.Physicians infrequently adhere to hepatitis vaccination guidelines for chronic liver disease.Educational opportunities in bladder cancer: increasing cystoscopic adherence and the availability of smoking-cessation programs Patterns of surveillance imaging after nephrectomy in the Medicare population.Intravesical chitosan/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancer Variation in performance of candidate surgical quality measures for muscle-invasive bladder cancer by hospital type Surveillance and treatment of non-muscle-invasive bladder cancer in the USA.Clinical Practice Pattern of Immediate Intravesical Chemotherapy following Transurethral Resection of a Bladder Tumor in Korea: National Health Insurance Database Study Recurrence of high-risk bladder cancer: a population-based analysis.Noninvasive multianalyte diagnostic assay for monitoring bladder cancer recurrence.Single, immediate postoperative instillation of chemotherapy in non-muscle invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials using different drugs.Challenges in the pathology of non-muscle-invasive bladder cancer: a dialogue between the urologic surgeon and the pathologist.Trends in medical management of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.The value of EORTC risk tables in evaluating recurrent non-muscle-invasive bladder cancer in everyday practice.Current strategies in the treatment of non-muscle-invasive bladder cancer.Improving bladder cancer patient care: a pharmacoeconomic perspective.The future of bladder cancer care in the USA.Strategies to improve quality of life in bladder cancer patients.Optimal treatment of non-muscle invasive urothelial carcinoma including perioperative management revisited.Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.Future directions in bladder cancer immunotherapy: towards adaptive immunity.Association Between Number of Endoscopic Resections and Utilization of Bacillus Calmette-Guérin Therapy for Patients With High-Grade, Non-Muscle-Invasive Bladder Cancer.Non-muscle invasive bladder cancer: Are epicrises the 'Bermuda Triangle' of information transfer?Bladder cancer: Elderly and female patients fare the worst and deserve better.Delivering high-quality care to prostate cancer survivors.Implementing risk-aligned bladder cancer surveillance care.Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines.Clinical utility of a non-invasive urine test for risk assessing patients with no obvious benign cause of hematuria: a physician-patient real world data analysis.Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapy.Swedish National Registry of Urinary Bladder Cancer: No difference in relative survival over time despite more aggressive treatment.

P2860

Q26775979-BF281147-C3AB-4BFB-9BD2-4C6D912584E3 Q28542873-966368D7-1BA7-42B9-8165-A5E60435A3F0 Q30596342-29C9F897-77FA-49E7-8D01-602E573D466E Q33865957-37BC3925-A913-44CB-83E4-912BAB5D5E1E Q34026715-ED4FCDD5-55DA-414D-A02D-0B5BD39A68AB Q34210983-A2285429-7E6A-4821-9399-0A072BDBB691 Q34758436-9376E147-8AB1-48F7-A12C-1175AE00B4A9 Q34901035-92372531-E445-45F2-8739-82EE6304F0D1 Q34907938-7B251742-5FD9-46A0-BE0D-12EF8FD6DA1D Q35545878-864792B2-B570-4948-B89B-6728346CBE6B Q35589571-D560B70D-3D21-4C7F-B2BC-F07E03215737 Q35690511-809BAA3E-3707-4ECC-9C5A-5094152C8D8C Q35756074-D48E7E9E-4A75-4B9F-8E18-E9579B050ACB Q35977496-12DF7499-5830-4E2F-B4B0-37E2CA06946D Q36687904-0BD022A2-3697-4BEC-AE78-9ED2E4A75DC6 Q37171429-E40A1D6E-B1CC-4399-91F3-77EA3F5AE0B5 Q37250675-1CC6454E-6B27-4D1B-ADCE-247F9EB9A13F Q37564451-4DEF9B8E-A5F4-437E-872F-55C5438F708F Q37577902-1E6571AD-E9A8-4075-83D8-065CFF94B3E0 Q37656444-C1CFA761-D3B3-4E43-B504-BE0B5CB067D3 Q37711567-9976B926-C31E-4F8B-B193-6B43F756B198 Q38048823-D99AB4DF-9E88-4F66-BA1A-4FFC1B5E45EE Q38114945-09B5FAE1-3835-48DD-80EF-728B22CD5301 Q38131725-C4FF135F-3078-478C-8FB7-D554B91CF33F Q38210653-87953375-C78F-442E-B590-C6C190A562FD Q38252387-ED8F9D61-1DD0-47A2-BA0F-BF195F4A813C Q38621223-66238BC2-46B6-4C07-A499-14719903A7B9 Q38727522-22B1A5C2-A16C-4789-B7AC-7A9437870C64 Q39586831-450692F2-E91D-46B4-BE9E-3CD810690D14 Q43208189-09E7920E-1A8A-4E41-A7FE-D142ED798C0A Q43894149-8C39532D-00A1-430B-BE6B-95FBFA6C7785 Q48197856-11FB1DBC-3D25-43F4-9243-0D0FD1CAD5D6 Q48507562-B41566A7-2A13-4A5D-ACA7-0BC163E1C357 Q51227501-8C25E49E-FB55-4FE7-A6FC-A4D988781BD3 Q51742103-75692CA4-47C2-427C-AABD-37DBABCC95B3 Q53098848-B155D289-0EA9-4B8D-8434-7F54C61AEB1E Q53346507-BA4B4971-60FB-4F20-9DA8-3353E8BDA269

P2860

Compliance with guidelines for patients with bladder cancer: variation in the delivery of care.

http://www.wikidata.org/entity/Q35501135

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Compliance with guidelines for ...... ation in the delivery of care.

@ast

Compliance with guidelines for ...... ation in the delivery of care.

@en

type

label

Compliance with guidelines for ...... ation in the delivery of care.

@ast

Compliance with guidelines for ...... ation in the delivery of care.

@en

prefLabel

Compliance with guidelines for ...... ation in the delivery of care.

@ast

Compliance with guidelines for ...... ation in the delivery of care.

@en

P1433

Q35501135-CEAC6C88-3268-43B4-A0F6-819900009603

P1476

Q35501135-6E9CFC53-17C9-45C9-A8A1-3F2586D9EB96

P2093

Q35501135-17B97B98-4142-4BA5-A3E2-0E3E5DBFC1C8

Q35501135-35F86657-B2B6-4977-8AB4-A251B59A653E

Q35501135-A0544807-5AA4-417B-88E8-D7D41644B7E7

Q35501135-AADE7C59-1AF3-454F-8BFE-C62920EFAA9B

Q35501135-B54B72F0-1435-48C5-A783-5764AAF9D8A3

Q35501135-C3B776F0-E17A-428B-8D09-74411078373C

Q35501135-E26BB40A-B0FE-4EA4-8865-67F7B53ACE81

Q35501135-F7476EDB-366F-492E-9C19-6FD0D7EC0438

P2860

Q35501135-02348F98-326D-49B9-9C3E-0576412B217E

Q35501135-08096D62-B2A4-441A-9A5D-06B68DDA152A

Q35501135-230BF3DD-97FC-4C76-93DF-9E0049B3554E

Q35501135-4AF783EF-F439-484F-98AE-243A995B6F09

Q35501135-4B1C4DAB-803C-40C1-90EF-F3D98AF6358F

Q35501135-5A2084DA-E2C9-480F-B870-4D680BEC5A33

Q35501135-5D01005A-0382-407E-8F0E-C8AE72FB9844

Q35501135-5DE95A66-B5A4-4CCC-9E74-24CE51A425BA

Q35501135-620A1522-B217-4565-AF81-73CA997FC8A8

Q35501135-72F57239-47E6-461F-B71A-F62BCFA275F3

P304

Q35501135-42A997EB-A293-4E54-ACFC-DA8D46083845

P31

Q35501135-22D2046F-A84B-4384-B997-3BBFE3421959

P356

Q35501135-DB21B90E-5476-4A34-846B-37737C882FE9

P407

Q35501135-9E3546FF-67CA-49CD-BEE7-46F17D7117F1

P433

Q35501135-CDF05FAF-B8B3-4965-A84F-D623F264654A

P478

Q35501135-8470C720-04E7-4877-8F4D-3F599AC40F93

P577

Q35501135-C1DEEF64-828A-43ED-9D00-EF813979A51D

P5875

Q35501135-2AAEF5EF-00F7-4E66-99AC-88BD9298841D

P698

Q35501135-7F9D958E-A204-4FA7-92ED-6E52DE95BDBE

P932

Q35501135-DFFCF0F4-623E-49DA-ADAE-889C7F1939BF

P356

P1433

P1476

Compliance with guidelines for ...... ation in the delivery of care.

@en

P2093

Badrinath R Konety

http://www.w3.org/2001/XMLSchema#string

Christopher S Saigal

http://www.w3.org/2001/XMLSchema#string

Claude M Setodji

http://www.w3.org/2001/XMLSchema#string

Jan M Hanley

http://www.w3.org/2001/XMLSchema#string

Julie Lai

http://www.w3.org/2001/XMLSchema#string

Karim Chamie

http://www.w3.org/2001/XMLSchema#string

Mark S Litwin

http://www.w3.org/2001/XMLSchema#string

Urologic Diseases in America Project

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2010

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Development of a comorbidity index using physician claims data.

Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Patterns of care for early stage bladder cancer.

Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations.

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.

Use of radical cystectomy for patients with invasive bladder cancer.

The health economics of bladder cancer: a comprehensive review of the published literature.

Diffusion of surgical innovation among patients with kidney cancer.

P304

5392-5401

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.26198

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230224403

http://www.w3.org/2001/XMLSchema#string

P698

21780079

http://www.w3.org/2001/XMLSchema#string

P932

3206145

http://www.w3.org/2001/XMLSchema#string